Latest News for BIXT
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism,…
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide…
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIXT.
U.S. House Trading
No House trades found for BIXT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.